Inversago Pharma
Montreal, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $95M
Overview
Developing novel, peripherally-acting CB1 blockers to treat metabolic disorders without CNS side effects.
Metabolic
Technology Platform
A proprietary chemistry platform for designing peripherally-restricted inverse agonists of the cannabinoid receptor-1 (CB1) to treat metabolic disorders without CNS side effects.
Funding History
1Total raised:$95M
Series B$95M
Opportunities
Potential to become the standard of care for hyperphagia in Prader-Willi syndrome and address unmet needs in diabetic complications.
Risk Factors
Clinical efficacy in later-stage trials remains unproven, and the historical stigma of CB1 antagonists presents a commercial hurdle.
Competitive Landscape
Occupies a specialized niche reviving a previously failed mechanism, with limited direct competition but facing comparisons to highly effective GLP-1 therapies.